Supply of various vaccines

Medicines RFP Closed

PHARMAC invites proposals for the supply of various vaccines in New Zealand.

Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested suppliers to register with GETS and subscribe to this RFP to be kept up to date.

This request for proposals (RFP) letter incorporates the following schedules:

  • Schedule 1 specifies the vaccines for which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
  • Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
  • Schedule 3 sets out information about the estimated size of the current funded market for the various vaccines;
  • Schedule 4 [DOC, 264 KB] contains the RFP form in which you are to provide details of your proposal; and
  • Schedule 4b [XLSX, 34 KB] (Excel spreadsheet);
  • Schedule 5 [DOCX, 240 KB], linked but also available via GETS sets out PHARMAC’s proposed terms and conditions for supply of vaccines that will apply if your proposal is awarded.
Vaccines RFP document in .pdf [PDF, 233 KB]

If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) no later than 4.00 p.m. (New Zealand time) on Thursday 24 March 2016.

If you have any questions about this RFP you should submit them via GETS or alternatively by email

Please note that any additional information that PHARMAC gives to you as a result of your enquiry will also be given by PHARMAC to other potential suppliers, if PHARMAC determines that such information is material.

Schedule 1: Vaccine, background to RFP and types of proposals sought


PHARMAC is interested in considering any proposal from suppliers of various vaccines as listed in Tables 1 and 2 below:

Table 1. Currently funded vaccines

Vaccine description Currently listed brand(s)
Adult diphtheria and tetanus vaccine ADT Booster
Bacillus Calmette-Guerin vaccine BCG Vaccine
Diphtheria, tetanus and pertussis vaccine Boostrix
Diphtheria, tetanus, pertussis and polio vaccine Infanrix IPV
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine Infanrix-hexa
Haemophilus influenzae type B vaccine Act-HIB
Hepatitis A vaccine Havrix & Havrix Junior
Hepatitis B recombinant vaccine HBvaxPRO
Human papillomavirus vaccine Gardasil
Measles, mumps and rubella vaccine M-M-R II
Meningococcal (groups A, C, Y and W-135) congugate vaccine Menactra
Meningococcal C congugated vaccine  Neisvac-C
Pneumococcal vaccine Prevenar 13
Pneumococcal (PPV23) polysaccharide vaccine Pneumovax 23
Poliomyelitis vaccine IPOL
Rotavirus live reassortant oral vaccine RotaTeq
Varicella vaccine Varilrix
Tuberculin PPD (Mantoux) test TUBERSOL

Table 2. Currently unfunded vaccines

Vaccine description
Adult zoster vaccine

See the eligibility criteria below and possible amendments following this RFP.

Background to RFP

PHARMAC first issued a RFP for the supply of vaccines in June 2013, which resulted in agreements with five suppliers. Sole supply status for vaccines covered by those agreements expires on 30 June 2017.

PHARMAC is now seeking proposals for the supply of the vaccines as stated in Table 1 and 2 above, including proposals for sole supply during the period 1 July 2017 to 30 June 2020.

The New Zealand National Immunisation Schedule sets out the series of vaccines that are offered free to babies, children, adolescents and adults(external link)

In preparation for this RFP, PHARMAC requested that suppliers submit applications to PHARMAC for funding of any new or alternative brands of vaccines they may have available for supply from July 2017 and any proposed changes to the funding eligibility criteria for current listings and/or the Immunisation Schedule.

PHARMAC subsequently sought clinical advice from the Immunisation Subcommittee (Subcommittee) of PTAC on:

  • the suitability of new vaccines recently registered by Medsafe or planned to be registered in time for 2017 supply;
  • interchangeability of alternative brands; and
  • possible funding eligibility criteria changes.

The Immunisation Subcommittee of PTAC minutes are available on our website.

Below are some factors that you should consider in preparing a response to this RFP.

Eligibility Criteria

The current eligibility criteria for funded Vaccines can be found on our website.

As part of this RFP process, we may consider amending the eligibility criteria for the vaccines described below:

Varicella vaccine

Varicella vaccination is currently funded for high risk patients. PHARMAC is interested in proposals that would enable the funding of a universal childhood varicella single dose vaccination, possibly with catch-up programme.

Human papillomavirus vaccine (HPV)

HPV is currently funded for eligible females aged under 20 years and for specified high risk patients. The normal administration is for three doses to be administered over six months, to females aged 12.

PHARMAC is interested in proposals that would enable universal access as follows:

  • Reducing the number of doses to two, for girls up to the age of 15.
    • Note that the three dose vaccination would remain funded for females over the age of 15 up to 20 years as well as the high risk patients as per the current eligibility criteria.
  • Widening access to males aged 11-13.

Zoster vaccine

PHARMAC is interested in proposals that would enable funding of a single adult zoster vaccination for all patients at 65 years of age (‘universal vaccination)’, possibly with a catch-up programme for all adults who are over 65 years at the time the vaccine was listed.

Meningococcal C congugated vaccine

Meningococcal C congugated vaccination is currently funded for high risk patients. PHARMAC is interested in proposals that would enable the funding of a universal childhood meningococcal C vaccination, possibly with a catch-up programme.

Diphtheria, tetanus and pertussis vaccine

PHARMAC currently funds both:

  • an adult diphtheria and tetanus vaccine (ADT Booster); and
  • a diphtheria, tetanus and pertussis vaccine (Boostrix).

Each vaccine is funded under different eligibility criteria. PHARMAC is interested in proposals that would enable the funding of a single vaccine to cover both sets of current eligibility criteria (i.e. the eligibility criteria would be merged).


PHARMAC will place purchase orders for vaccines with the supplier. Such purchase orders will be required to be delivered to a designated delivery point, currently PHARMAC’s storage and distribution service provider as follows:

PHARMAC c/o HealthCare Logistics
HealthCare Logistics
58 Richard Pearse Drive, Airport Oaks
Auckland 2022
New Zealand

Contract duration

Any resulting contract(s) from this RFP process would be evergreen and would include  a maximum sole supply period of three years, from no earlier than 1 July 2017 to no later than 30 June 2020. During this period the eligibility criteria may change and any contract(s) resulting from this process would provide for this (see Schedule 5).

Types of proposals sought

Sole Supply

Sole supply status would entail both sole subsidised supply in the Community via a listing in Section I of the Pharmaceutical Schedule (i.e. the National Immunisation Schedule) and hospital supply status in Part II of Section H of the Pharmaceutical Schedule.

PHARMAC is willing to consider the following types of proposals for sole supply status, where the supplier is expected to meet the demand for all doses of that vaccine, from no earlier than 1 July 2017 to no later than 30 June 2020:

  1. Proposals for a single vaccine with sole supply status.
  2. Proposals that bundle multiple vaccines with sole supply status.

Suppliers may submit multiple proposals for a single vaccine or bundles of vaccines as described in a. and b. above.

Please note if you wish to submit a bundle proposal for vaccines, you must also submit at least one individual proposal for each of the vaccines included in the bundle.

Outbreak supply

Other types of proposals

Suppliers may also like to submit other types of proposals. Possibilities include:

  1. Proposals that include rebate arrangements, where the purchase price may be different from the net price offered to PHARMAC for the vaccine.
  2. Proposals that would enable PHARMAC to fund changes to eligibility criteria as outlined in Schedule 1 eligibility criteria.

Please note:

  • If you wish to submit a proposal for widened access, you must also submit a proposal for the current access criteria.

Proposal pricing

When submitting pricing please note the following:

  1. PHARMAC is seeking a purchase price from suppliers for each vaccine, this is the price that PHARMAC will be invoiced by a supplier, which is expected to be confidential between the supplier and PHARMAC.
  2. Any vaccine listed as a result of this RFP in Section I or Part II of Section H of the Pharmaceutical Schedule